RxDoctor Payments Data

Trung Vu, MD

Infectious Disease · Greensboro, NCNPI 1619006137

Payments from drug & device makers

$1,197in general payments, 2019–2025

Across 57 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$328
  • Gilead$210
  • Insmed, Inc.$190
  • Merck$112
  • Melinta Therapeutics, LLC$81
  • Janssen Products, LP$70
  • plus $205 from 8 others

What the payments were for

  • Food & beverage$1,10192%
  • Education$968%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,197 in reported general payments places this provider in the 60th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,233
Medicare patients
117
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala56$239,893
DovatoDolutegravir Sodium/Lamivudine42$126,444
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$50,735
CompleraEmtricita/Rilpivirine/Tenof Df13$46,345
TivicayDolutegravir Sodium15$32,390
Penicillin G Potassium13$5,558
Cefadroxil87$3,196
Cefazolin Sodium26$1,964
Fluconazole12$1,295
Cefepime Hcl12$492
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$401
Doxycycline Hyclate15$380
Cephalexin18$293
Triamcinolone Acetonide14$103
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$210$290,62967 claims
Viiv Healthcare CompanyDovato, Tivicay$328$158,83457 claims
Johnson & JohnsonComplera$40$46,34513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →